research ZnO@PDA@Ag Nanocomposite-Mediated Delivery of 9-Bromonoscapine, an Anticancer Agent, for Enhanced Lung Cancer Therapy
The nanocomposite effectively targets lung cancer cells without harming normal cells.
Search
for
Sort by
Research
390-420 / 1000+ results
research XMU-MP-1 induces growth arrest in a model human mini-organ and antagonises cell cycle-dependent paclitaxel cytotoxicity
XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor
ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.
research Nilontinib induced keratosis pilaris atrophicans
Nilotinib can cause skin issues like red bumps and hair loss.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab can cause skin issues, but baricitinib may help improve them.
research A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4
The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.
research The Development of BL 7660 as an Anti‐Acne Agent
BRL 7660, once studied for male contraception, showed promise as an acne treatment but was not developed further due to competing drugs.
research Recent discoveries and developments of androgen receptor based therapy for prostate cancer
New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
research Erlotinib induced acneiform eruption: A case report
Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research Loose anchoring of anagen hairs and pili torti due to erlotinib
Erlotinib can cause hair loss and texture changes.
research Ultrasound-Assisted Facile Synthesis and Anticancer Evaluation of Novel N-(2-substituted phenyl-4-oxathiazolidine-3-carbonothioyl) benzamide
Researchers made new compounds that could potentially be developed into anticancer drugs.
research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research ONKOLOGIA OKULISTYCZNA WCZORAJ I DZIŚ
Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
research RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Examination of epigenetic inhibitor zebularine in treatment of skin wounds in healthy and diabetic mice
Zebularine improved skin structure but delayed wound healing in diabetic mice.